XNAS · Healthcare · Biotechnology
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Q1 2026 | -0.20 | -0.14 | +30.00% | $8.3M | ✅ Beat | -2.67% | -20.76% | — |
| 2026-02-24 | Q4 2025 | -0.18 | -0.03 | +83.33% | $44.9M | ✅ Beat | +8.70% | +15.22% | +4.04% |
| 2025-11-06 |
| Q3 2025 |
| -0.17 |
| -0.19 |
| -11.76% |
| $9.0M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-07 | Q2 2025 | -0.17 | -0.12 | +29.41% | $17.1M | ✅ Beat | +21.46% | +6.13% | -0.47% |
| 2025-02-27 | Q4 2024 | -0.15 | -0.12 | +20.00% | $5.1M | ✅ Beat | -11.47% | -18.49% | -23.63% |
| 2024-11-04 | Q3 2024 | -0.15 | -0.17 | -13.33% | $6.5M | ❌ Miss | -5.88% | +9.00% | +0.35% |
| 2024-08-06 | Q2 2024 | -0.14 | -0.13 | +7.14% | $7.3M | ✅ Beat | -7.72% | -6.32% | -14.74% |
| 2024-05-07 | Q1 2024 | -0.17 | -0.14 | +17.65% | $10.0M | ✅ Beat | -4.95% | -5.45% | -6.44% |
Showing last 8 quarters.